Gastroenterology Research and Practice

Novel Molecular Targets in Malignant Diseases of Digestive System


Publishing date
20 Dec 2013
Status
Published
Submission deadline
02 Aug 2013

Lead Editor

1Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

2Transplantation Surgery Division, University of Arkansas for Medical Sciences, Little Rock, AR, USA

3Department of Transplantation and Hepatic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, China

4Harvard Medical School, Boston, MA, USA


Novel Molecular Targets in Malignant Diseases of Digestive System

Description

Malignant diseases of digestive system represent a significant health problem worldwide. In recent years, the advances in mechanisms of digestive system cancers have revealed multiple molecular pathways participating in the process of carcinogenesis, angiogenesis, tumor microenvironment, metastasis, and so forth. These findings lead to the innovation of novel molecular-targeted therapeutics including multikinase inhibitor sorafenib for hepatocellular carcinoma, c-kit inhibitor imatinib for gastrointestinal stromal tumor, and VEGF-targeting bevacizumab for colorectal cancer, which have significantly improved the prognosis of these malignancies. Upcoming research on potential molecular targets in digestive system tumors will have distinguished significance in novel drug development and may have a direct impact on clinical practice.

We are particularly interested in studies reporting novel molecular targets in digestive system cancers with relevance to carcinogenesis, tumor malignant behavior, prognosis prediction, or monitoring of therapy. Manuscripts delineating potential molecular targeting compounds or biochemical intervention with mechanism discussion would be of great interest. Reviews that summarize recent improvements in novel molecular targets and novel therapeutic innovations in malignancies of digestive system are also welcome. Potential topics include, but are not limited to:

  • Molecular targets in carcinogenesis
  • Molecular targets in metastasis (cancer cell motility, invasion, epithelial to mesenchymal transition, etc.)
  • Molecular targets in tumor microenvironment (tumor immunity, tumor-associated stromal cells, messengers between cancer cell and microenvironment, etc.)
  • Molecular targets in cancer-associated inflammation
  • Clinical significance of molecular pathways
  • Novel targeted compounds and biochemical interventions

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/grp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/grp/mdds/ according to the following timetable:

Gastroenterology Research and Practice
 Journal metrics
See full report
Acceptance rate5%
Submission to final decision98 days
Acceptance to publication22 days
CiteScore3.900
Journal Citation Indicator0.370
Impact Factor2.0
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.